August 29, 2022
RFA-CA-22-028: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)
RFA-CA-22-029: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
RFA-CA-22-030: Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
The National Cancer Institute (NCI) will hold a pre-application webinar on Wednesday, September 7, 2022 from 4:00 PM to 6:00 PM (EDT) for the Funding Opportunity Announcements (FOAs) RFA-CA-22-028 “Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)”, RFA-CA-22-029 "Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)", and RFA-CA-22-030 "Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed)."
NCI staff members involved in these FOAs will provide orientation and programmatic guidance to potential applicants by explaining the goals and objectives of the Can-ACT Network and answering questions from attendees. Potential applicants are encouraged to submit their questions by September 5, 2022 via email to [email protected]. Questions can also be asked spontaneously at the webinar. The webinar will be recorded and made available for those unable to attend the live event. The recording may be requested by contacting Zhang-Zhi Hu at [email protected]. Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to RFA-CA-22-028, RFA-CA-22-029, and RFA-CA-22-030.
Webinar Information
To join the webinar, pre-registration is required through WebEx at https://cbiit.webex.com/cbiit/j.php?RGID=r2f98bbe19d7ed72e93f3b7737900a3d3. The link for joining the webinar will be provided upon registration.
Webinar Date: September 7, 2022
Time: 4:00 PM to 6:00 PM EDT
Kasia Bourcier, Ph.D.
National Cancer Institute (NCI)
Telephone: 202-657-7589
Email: [email protected]
Zhang-Zhi Hu, M.D.
National Cancer Institute (NCI)
Telephone: 202-731-8819
Email: [email protected]
Anju Singh, B.V.Sc, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7603
Email: [email protected]